TY - JOUR
T1 - Role of Liquid Biopsy in Clinical Decision-Making for Breast Cancer
AU - Hall, Carolyn S
AU - Sarli, Vanessa
AU - Meas, Salyna
AU - Lucci, Anthony
PY - 2019/6/15
Y1 - 2019/6/15
N2 - Purpose of Review: Liquid biopsies are easily obtainable, non-invasive, longitudinal snapshots that can be used to measure micrometastatic disease burden, monitor disease progression, and provide genomic assessments of primary tumor/metastatic lesions. To date, most published studies have focused on circulating tumor cells (CTCs) and cell-free circulating tumor DNA (ctDNA); however, the liquid biopsy field is expanding exponentially and new blood components are currently under investigation. Recent Findings: CTCs and ctDNA remain the most extensively studied liquid biopsy components to date. Several additional blood-based components are the basis of active, ongoing investigations. Some on the horizon include serum/plasma exosomes, platelet-mRNA, miRNA characterization, and global proteomic studies. Summary: In the era of individualized medicine, liquid biopsy has potential to improve upon current breast cancer management by offering dynamic monitoring possibilities as well as novel targets for therapy.
AB - Purpose of Review: Liquid biopsies are easily obtainable, non-invasive, longitudinal snapshots that can be used to measure micrometastatic disease burden, monitor disease progression, and provide genomic assessments of primary tumor/metastatic lesions. To date, most published studies have focused on circulating tumor cells (CTCs) and cell-free circulating tumor DNA (ctDNA); however, the liquid biopsy field is expanding exponentially and new blood components are currently under investigation. Recent Findings: CTCs and ctDNA remain the most extensively studied liquid biopsy components to date. Several additional blood-based components are the basis of active, ongoing investigations. Some on the horizon include serum/plasma exosomes, platelet-mRNA, miRNA characterization, and global proteomic studies. Summary: In the era of individualized medicine, liquid biopsy has potential to improve upon current breast cancer management by offering dynamic monitoring possibilities as well as novel targets for therapy.
KW - Breast cancer
KW - Circulating tumor DNA
KW - Circulating tumor cells
KW - Liquid biopsy
UR - http://www.scopus.com/inward/record.url?scp=85067976272&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85067976272&partnerID=8YFLogxK
U2 - 10.1007/s12609-019-0308-0
DO - 10.1007/s12609-019-0308-0
M3 - Review article
AN - SCOPUS:85067976272
SN - 1943-4588
VL - 11
SP - 52
EP - 66
JO - Current Breast Cancer Reports
JF - Current Breast Cancer Reports
IS - 2
ER -